<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04876118</url>
  </required_header>
  <id_info>
    <org_study_id>ZA20-002</org_study_id>
    <nct_id>NCT04876118</nct_id>
  </id_info>
  <brief_title>Effects on Cellulite Appearance</brief_title>
  <acronym>EFC</acronym>
  <official_title>Feasibility Study of CoolSculpting Effects on Cellulite Appearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeltiq Aesthetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeltiq Aesthetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and feasibility effecting the appearance of cellulite on the thigh using&#xD;
      CoolSculpting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visible changes in the treated areas on Photos</measure>
    <time_frame>one-month post final data collection</time_frame>
    <description>Comparison of baseline and 12-week post-final treatment photographs to assess visible changes in the treated areas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE's</measure>
    <time_frame>one-month post final data collection</time_frame>
    <description>The frequency of device and procedure-related adverse events (AEs), including device-related serious adverse events (SADEs), will be summarized. Safety Endpoint:</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Body Fat Disorder</condition>
  <arm_group>
    <arm_group_label>Fat Reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatments are designed to see if the appearance of cellulite can be reduced on the outer thigh with a new applicator design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The ZELTIQ System</intervention_name>
    <description>The CoolSculpting machine will be used to perform the treatments.</description>
    <arm_group_label>Fat Reduction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Female subjects &gt; 22 years of age and &lt; 65 years of age.&#xD;
&#xD;
          -  Subject has clearly visible cellulite on the intended treatment area (thighs), which&#xD;
             in the Investigator's opinion, may benefit from the treatment.&#xD;
&#xD;
          -  Subject has not had weight change exceeding 5% in the preceding month.&#xD;
&#xD;
          -  Subject agrees to maintain her weight (i.e., within 5%) by not making any major&#xD;
             changes in diet or exercise routine during the course of the study.&#xD;
&#xD;
          -  Subject has read and signed a written informed consent form.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Subject has had a surgical procedure(s) in the area of intended treatment.&#xD;
&#xD;
          -  Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy)&#xD;
             in the area of intended treatment.&#xD;
&#xD;
          -  Subject has had a non-invasive fat reduction, body contouring, cellulite reduction&#xD;
             and/or skin tightening procedure in the area of intended treatment within the past 4&#xD;
             months.&#xD;
&#xD;
          -  Presence of significant suntan in the thighs.&#xD;
&#xD;
          -  Inability to avoid sun exposure in the thighs.&#xD;
&#xD;
          -  Subject has a history of hernia in or adjacent to the areas to be treated.&#xD;
&#xD;
          -  Subject needs to administer or has a known history of subcutaneous injections into the&#xD;
             area of intended treatment (e.g., heparin, insulin) within the past month.&#xD;
&#xD;
          -  Subject has a known history of cryoglobulinemia, cold urticaria, cold agglutinin&#xD;
             disease, or paroxysmal cold hemoglobinuria.&#xD;
&#xD;
          -  Subject has a known history of Raynaud's disease, or any known condition with a&#xD;
             response to cold exposure that limits blood flow to the skin.&#xD;
&#xD;
          -  Subject has a history of bleeding disorder or is taking any medication that in the&#xD;
             Investigator's opinion may increase the subject's risk of bruising.&#xD;
&#xD;
          -  Subject has known sensitivity or allergy to isopropyl alcohol and propylene glycol.&#xD;
&#xD;
          -  Subject is taking or has taken diet pills or supplements within the past month.&#xD;
&#xD;
          -  Subject has any dermatological conditions, such as moderate to excessive skin laxity,&#xD;
             or scars in the location of the treatment sites, that may interfere with the treatment&#xD;
             or evaluation (stretch marks is not an exclusion).&#xD;
&#xD;
          -  Subject has an active implanted device such as a pacemaker, defibrillator, implants&#xD;
             (e.g. buttock implants), or drug delivery system.&#xD;
&#xD;
          -  Subject is pregnant or intending to become pregnant during the study period (in the&#xD;
             next 9 months).&#xD;
&#xD;
          -  Subject is lactating or has been lactating in the past 6 months.&#xD;
&#xD;
          -  Subject is unable or unwilling to comply with the study requirements.&#xD;
&#xD;
          -  Subject is currently enrolled in a clinical study of any other unapproved&#xD;
             investigational drug or device.&#xD;
&#xD;
          -  Any other condition or laboratory value that would, in the professional opinion of the&#xD;
             Investigator, potentially affect the subject's response or the integrity of the data&#xD;
             or would pose an unacceptable risk to the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori Brandt, BSN</last_name>
    <role>Study Director</role>
    <affiliation>Zeltiq Aesthetics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tonia N Madere</last_name>
    <phone>925-474-2537</phone>
    <email>tonia.madere@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Innovation Research Center</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Akbari</last_name>
      <phone>925-474-2501</phone>
      <email>clinicalstudy@pleasantonirc.com</email>
    </contact>
    <contact_backup>
      <last_name>Theresita Gray, RN</last_name>
      <phone>925-474-2501</phone>
      <email>clinicalstudy@pleasantonirc.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

